Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Spyre Therapeutics (NASDAQ:SYRE) has received a "Moderate Buy" consensus rating from fifteen brokerages, with an average 12-month price target of $111.69. The stock has shown volatility, opening near its 52-week high, and the company recently reported better-than-expected quarterly earnings. Despite institutional ownership being high, insiders have been selling shares.
Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?
Spyre Therapeutics (SYRE) has launched its SPY772 combination program and initiated the SKYLIGHT Phase 2 trial for Hidradenitis Suppurativa, targeting dual inhibition of TL1A and IL-17A/F. Despite strong recent share price performance and a P/B ratio of 10.1x (compared to the US biotech average of 2.5x), analysts set a target price near US$124.71, suggesting the stock might be fully priced. The article highlights that while the market shows considerable optimism for its clinical programs, key risks like trial setbacks and potential equity dilution remain.
Price to book forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE
This page displays the "Price to book forward" metric for Spyre Therapeutics, Inc. (NASDAQ: SYRE). It indicates a financial ratio for the company, and while the specific value is not shown, the page structure suggests it's part of a detailed financial overview provided by TradingView.
Spyre Therapeutics stock hits 52-week high at 108.16 USD By Investing.com
Spyre Therapeutics (SYRE) stock has reached a 52-week high of $108.16, marking significant growth with a 517% return over the past year and a 219% gain year-to-date, pushing its market capitalization to $9.5 billion. This surge follows positive phase 2 trial results for its ulcerative colitis drug SPY002, though some analysts express concerns about valuation despite overall strong buy recommendations. A significant insider selling event by Fairmount Healthcare Fund II L.P. also occurred.
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) recently hit a new 52-week high of $108.52, bringing its market capitalization to approximately $9.46 billion. Analysts generally maintain a "Moderate Buy" rating with an average price target of $111.69, and the company exceeded quarterly EPS expectations. Despite this positive performance, insiders sold $12.8 million worth of shares over the last quarter.
Spyre Therapeutics stock hits 52-week high at 108.16 USD
Spyre Therapeutics (SYRE) stock reached a 52-week high of $108.16, reflecting a 517% return over the past year and a 219% gain year-to-date, with a market capitalization of $9.5 billion. This surge follows positive phase 2 trial results for its ulcerative colitis drug SPY002 and analyst price target increases from Mizuho and Deutsche Bank, though some concerns about valuation and insider selling have also emerged. Investors are advised to consider comprehensive analysis, including InvestingPro’s insights and detailed financial health scores.
Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE
Handelsbanken Fonder AB has made a new $2.31 million investment in Spyre Therapeutics, Inc. by purchasing 26,000 shares. This comes as other institutional investors have also adjusted their holdings, and analysts maintain a "Moderate Buy" rating with an average price target of $111.69. Despite recent insider share sales totaling $12.8 million, the company reported better-than-expected quarterly EPS of -$0.36.
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell
Wall Street Zen has downgraded Spyre Therapeutics (NASDAQ:SYRE) from "hold" to "sell," despite a broader "Moderate Buy" consensus from other analysts with an average target price of $111.69. The company's shares opened at $103.63, near a 52-week high, and it reported a quarterly loss of $0.36 per share, outperforming the $0.76 consensus estimate. Insider selling of 142,167 shares worth $12.8 million occurred over the last 90 days, while institutional investors hold 80.39% of the stock.
Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 4.9% beneficial ownership stake in Spyre Therapeutics (SYRE) through a SCHEDULE 13G/A filing. This stake amounts to 4,319,496 shares of common stock, based on 88,173,762 shares outstanding as of July 28, 2026. The shares are directly held by the Master Fund, with Perceptive Advisors and Joseph Edelman having shared voting and dispositive power.
RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds
RTW Investments, LP and its managing partner, Roderick Wong, M.D., have reported a beneficial ownership of 4,251,996 shares of Spyre Therapeutics (SYRE) common stock, representing 4.8% of the outstanding shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong exercising shared voting and dispositive power. The ownership percentage is based on 87,936,477 shares outstanding as of June 24, 2026.
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE
Dimensional Fund Advisors LP has reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 38.3%, selling 29,593 shares but retaining 47,697 shares valued at $2.4 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $111.69, while institutional investors collectively own over 80% of the company. Insiders have sold 142,167 shares worth $12.8 million in the past 90 days, though Spyre recently surpassed EPS expectations.
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside
Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $126.85, up from $124.71, with individual forecasts ranging from $115 to $140. This new target suggests a potential upside of approximately 22% from its August 12 closing price. The consensus rating from 15 analysts remains a "Buy," with 14 recommending Buy and 1 recommending Hold.
Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920
This article provides financial data for Spyre Therapeutics, Inc (SWB:3920) listed on the Stuttgart Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades recorded for the stock. The content is primarily a data page from TradingView.
Price to book forward of Spyre Therapeutics, Inc – SWB:3920
This article provides financial information for Spyre Therapeutics, Inc. (SWB:3920) on the Stuttgart Stock Exchange, specifically focusing on its price-to-book forward ratio. It also highlights the various products, community features, and business solutions offered by TradingView, the platform hosting this financial data.
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says
BTIG Research has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) to $132 from $112, maintaining a "Buy" rating and suggesting a 25.32% upside. This positive outlook follows Spyre Therapeutics beating quarterly earnings expectations, though insiders have sold a significant amount of stock recently. The company currently holds a "Moderate Buy" consensus rating among analysts with an average target price of $111.69.
SYRE Maintained by BTIG -- Price Target Raised to $132.00
BTIG analyst Julian Harrison has maintained a 'Buy' rating for Spyre Therapeutics (SYRE) and raised its price target to $132.00 from $112.00. While analysts show growing confidence in SYRE's potential, the company has a low GF Score™ of 26/100, indicating weaknesses in profitability and growth, alongside significant insider selling activity. Investors are advised to proceed with caution due to potential overvaluation and the company's pre-revenue stage.
Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing
An insider at Spyre Therapeutics (SYRE) has reportedly sold shares valued at $2,404,190, according to a recent SEC filing. This transaction follows other insider sales and occurs as the company launches a new program and a mid-stage trial for a drug combination to treat Hidradenitis Suppurativa. Spyre Therapeutics is a clinical-stage biotechnology company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 192.6% in the first quarter, now holding 1.23 million shares valued at approximately $61.9 million. Institutional investors collectively own 80.39% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $110.15. Despite a recent quarterly loss, SYRE shares opened near their 52-week high, while company insiders have sold over $12.8 million worth of shares.
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares
Spyre Therapeutics (NASDAQ:SYRE) Director Jeffrey Albers sold 18,000 shares of the company's stock for $1,881,900, reducing his holdings by 65.79%. The transaction occurred as Spyre shares traded near record highs and the company reported strong quarterly earnings, beating analyst expectations. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating with an average price target of $110.15.
Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale
Jeffrey W. Albers, a director at Spyre Therapeutics (SYRE), exercised stock options for 5,000 shares and sold a total of 23,000 shares on August 7, 2026. The sales, which included indirect ownership through Sessions LLC, were executed at weighted average prices slightly above $104 per share, all under a pre-arranged Rule 10b5-1 trading plan adopted in April 2026. After these transactions, Albers retains options for 45,000 shares and an indirect holding of 9,360 common shares via Sessions LLC.
Spyre Therapeutics director Albers sells $2.4m in stock
Jeffrey W. Albers, a director at Spyre Therapeutics (NASDAQ:SYRE), sold 23,000 shares of common stock totaling approximately $2.4 million on August 7, 2026, under a Rule 10b5-1 trading plan. The sales occurred while the stock was near its 52-week high, with InvestingPro analysis indicating it is overvalued. Albers now directly holds no shares but retains indirect beneficial ownership and options for future share purchases.
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Spyre Therapeutics has announced the launch of its SPY772 program, a combination therapy involving long-acting anti-TL1A and anti-IL-17A/F antibodies, and the initiation of the Phase 2 SKYLIGHT trial for Hidradenitis Suppurativa (HS). The SKYLIGHT trial will evaluate the dual inhibition of TL1A and IL-17A/F in moderate-to-severe HS patients, with topline results expected in late 2027 or early 2028. This program aims to achieve superior efficacy and convenience for patients by targeting complementary inflammatory pathways.
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa
Spyre Therapeutics has initiated a Phase 2 trial, SKYLIGHT, for SPY772, a combination therapy targeting hidradenitis suppurativa (HS). The trial will evaluate the dual inhibition of TL1A and IL-17A/F using SPY072 and bimekizumab, with topline data expected in late 2027 or early 2028. This study aims to assess if adding SPY072 to existing bimekizumab treatment can improve outcomes for adults with moderate-to-severe HS.
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Spyre Therapeutics has launched its SPY772 program and initiated the Phase 2 SKYLIGHT trial for Hidradenitis Suppurativa (HS). The SPY772 program aims for best-in-indication efficacy through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation. The SKYLIGHT trial, expected to enroll 150 adults, will evaluate adding SPY072 (anti-TL1A) to bimekizumab (anti-IL-17A/F) to improve outcomes for moderate-to-severe HS patients, with topline results anticipated in late 2027 or early 2028.
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE
The California State Teachers Retirement System increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 23.3% in the first quarter, acquiring an additional 11,204 shares and now owning 59,242 shares valued at $2.988 million. This comes as institutional investors collectively own 80.39% of the company, and despite recent insider sales totaling $10.4 million. Spyre Therapeutics also reported better-than-expected quarterly earnings and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $110.15.
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?
Spyre Therapeutics has shown exceptional returns over the past three years, with its stock returning roughly 7x, but current valuations suggest it is expensive. The company recently announced positive Phase 2 data for its ulcerative colitis programs, which could support higher growth expectations. However, with the stock currently passing only one of six valuation checks and trading at a significant premium on a P/B basis compared to the broader biotech industry, its ability to justify its current price hinges on continued clinical and commercial progress through 2026.
Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE
This article displays the "Price to sales forward" metric for Spyre Therapeutics, Inc. (NASDAQ: SYRE) on TradingView. It appears to be a financial data page rather than a detailed analytical article, offering a single data point within the financial overview of the company.
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026)
This article details an SEC Form 144 filing by Spyre Therapeutics, Inc. (SYRE) on August 7, 2026, concerning a proposed sale of 5,000 shares with an aggregate market value of $517,100. The shares were acquired through the exercise of stock options on the same date. The filing is categorized as neutral in both impact and sentiment by StockTitan's AI.
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026)
This article reports on Spyre Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing details a proposed sale of 18,000 shares of common stock by an individual, acquired through an open market purchase in June 2022, with an aggregate market value of $1,861,560. The transaction is set to occur on August 7, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ.
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88
Raymond James has increased its target price for SPYRE THERAPEUTICS INC shares to $121 from $88. This update reflects a significant uplift in the analyst's valuation of the company. The news was reported by Reuters.
Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920
This article provides financial information for Spyre Therapeutics, Inc. trading on the Dusseldorf Stock Exchange under the ticker DUS:3920. It specifically mentions the "Price to earnings forward" metric but does not display any actual values, indicating the market is closed with no trades. The page is primarily a placeholder for financial data on TradingView.
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock
Cameron Turtle, CEO of Spyre Therapeutics (NASDAQ:SYRE), sold 15,000 shares of company stock worth over $1.43 million on August 3, 2026, as part of a pre-arranged trading plan. Despite these insider sales, the stock has seen a significant 554% gain over the past year and is trading near its 52-week high, following positive phase 2 trial results for its ulcerative colitis drug and increased price targets from some analysts. However, other recent developments include a downgrade from Wolfe Research due to valuation concerns and a large insider sale by Fairmount Healthcare Fund II L.P.
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares
Cameron Turtle, CEO of Spyre Therapeutics (SYRE), sold 15,000 shares for approximately $1.43 million, bringing his total sales over the past year to 165,000 shares with no purchases. This insider selling, coupled with no guru buys and two guru trims, indicates a cautious sentiment among informed market participants and suggests a potentially rich valuation for the clinical-stage biotech company. Investors are advised to perform careful due diligence given the consistent selling pressure and high market expectations.
Spyre Therapeutics (SYRE) CEO trades 15,000 shares under 10b5-1 plan
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on August 3, 2026, across five open-market transactions. These sales were conducted under a Rule 10b5-1 trading plan adopted in June 2025, with weighted average prices ranging from $93.97 to $97.46 per share. Following these transactions, the CEO still holds 567,540 shares, including 58,108 shares that will vest monthly through November 2026.
Spyre Therapeutics (SYRE) CFO sells 7,500 shares after option exercise
Spyre Therapeutics (SYRE) CFO Scott L. Burrows exercised stock options for 7,500 shares at $14.50 each and subsequently sold all 7,500 shares in three transactions at weighted average prices between $95.21 and $97.10. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted in November 2025. Following these sales, Burrows retains options for 344,857 shares and 67,476 restricted stock units.
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside
Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $119.43 from $105.79, implying a potential upside of 14% based on the August 4th closing price. The consensus rating from 16 analysts remains a "Buy," with 15 Buys and 1 Hold.
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Spyre Therapeutics (SYRE) reported a narrower-than-expected loss of 36 cents per share in Q2 2026, beating the Zacks Consensus Estimate of a 71-cent loss. The company's pipeline progressed significantly, with positive top-line data from its SKYLINE phase II study for SPY001 and SPY002 in ulcerative colitis. Spyre expects to deliver six phase II proof-of-concept readouts in 2026 and anticipates its current cash balance to fund operations into the second half of 2029.
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88
Raymond James has increased its target price for SPYRE THERAPEUTICS INC (SYRE.O) to $121 from $88. This information comes from a Reuters report published on August 5, 2026. The article's content reflects only the author's opinion and is not intended as investment advice.
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Spyre Therapeutics (SYRE) reported a Q2 2026 loss of 36 cents per share, which was narrower than the estimated 71 cents. The company, which has no marketed products, saw its operating expenses decrease slightly due to gains from the sale of an in-process R&D asset, offsetting increased R&D and G&A costs. Spyre also made significant pipeline progress with positive top-line data for two candidates in its SKYLINE phase II study and expects further readouts in late 2026 and 2027, projecting its current cash position to fund operations into late 2029.
Spyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary
Spyre Therapeutics, Inc. reported a net loss of $36.2 million for Q2 2026, a slight improvement from the $36.7 million loss in Q2 2025, with diluted loss per share at $(0.36). The company had no product revenue, with results primarily influenced by R&D spending, investment income, and milestone gains. Key business highlights include ongoing Phase 2 trials for SKYLINE and SKYWAY, positive clinical results for SPY001 and SPY002, increased R&D spending, and strategic partnerships for pipeline assets.
Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported its second-quarter 2026 financial results, which included cash and cash equivalents of $772.1 million. The company also provided a corporate update, highlighting progress in its clinical programs for IBD and outlining its financial outlook for the coming year.
Spyre expects six Phase 2 trial readouts in 2026; cash totals $1.1B
Spyre Therapeutics reported Q2 2026 financial results, highlighting positive topline induction data for SPY001 and SPY002 in ulcerative colitis. The company completed enrollment for its Phase 2 SKYWAY basket trial and anticipates six proof-of-concept Phase 2 readouts in 2026. Spyre also reported $1.1453 billion in cash and cash equivalents, projecting a cash runway into the second half of 2029.
Spyre Therapeutics stock hits 52-week high at 105.11 USD By Investing.com
Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $105.11, marking a significant 517.49% increase over the past year and achieving a market capitalization of $9.23 billion. This surge is driven by strong investor confidence and positive phase 2 trial results for its drug SPY002 targeting ulcerative colitis, leading to raised price targets from Mizuho and Deutsche Bank. However, InvestingPro suggests the stock may be overvalued, and Wolfe Research downgraded it due to valuation concerns and insider selling has also been reported.
Spyre Therapeutics stock hits 52-week high at 105.11 USD
Spyre Therapeutics stock reached a new 52-week high of $105.11, marking a significant 517.49% increase over the past year and pushing its market capitalization to $9.23 billion. Despite this growth and positive Phase 2 trial results for its ulcerative colitis drug, SPY002, InvestingPro analysis suggests the stock may be overvalued. Recent developments include raised price targets from Mizuho and Deutsche Bank, but also a downgrade from Wolfe Research due to valuation concerns and substantial insider selling.
SYRE (NASDAQ: SYRE) insider schedules 30,000-share stock sale notice
SYRE insider Scott Burrows has filed a Form 144 notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, related to the exercise of stock options. The aggregate value of this planned sale is $2,949,900.00. The filing also reports prior sales by Burrows, including 7,500 shares for $658,043.00 on July 1, 2026, under a 10b5-1 plan, and other sales in June 2026.
Spyre Therapeutics Inc (SYRE) Institutional Confidence
This article analyzes the institutional confidence in Spyre Therapeutics Inc (SYRE), highlighting its strong score of 10.00 within the Biotechnology & Medical Research industry. Institutional shareholding has increased by 19.72% quarter-over-quarter, with Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A. among the largest holders showing significant increases in their stake. The article provides a detailed breakdown of major institutional shareholders and their changes in holdings.
SYRE|Spyre Therapeutics Inc|Price:99.940|Chg%:-0.100
This article provides a comprehensive stock analysis of Spyre Therapeutics Inc. (SYRE), highlighting its relatively weak fundamentals but high growth potential, fair valuation, and strong institutional ownership. It details the company's clinical-stage biotechnology focus on inflammatory bowel disease (IBD) and other immune-mediated diseases, outlining its pipeline programs. The analysis also covers various scores including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment generated by TradingKey.
Wolfe Research downgrades Spyre stock rating on valuation concerns By Investing.com
Wolfe Research downgraded Spyre Therapeutics (NASDAQ:SYRE) to Peerperform from Outperform due to valuation concerns, setting a fair value range of $96 to $113 per share. The firm noted that the stock is currently trading at $100, near its 52-week high, and expressed a lack of confidence in upcoming Q3 catalysts. Despite a significant 489% stock surge over the past year and recent positive phase 2 trial results for SPY002, analysts find it difficult to build a thesis around M&A activity given numerous upcoming catalysts, though some analysts have raised price targets citing promising data.
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Spyre Therapeutics Inc (SYRE), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the overall signal is Neutral according to technical analysis, the moving averages show more buy signals than sell signals.
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Spyre Therapeutics Inc's (SYRE) dividend and stock split history. It indicates that SYRE has distributed no dividends over the past five years. The company did experience multiple "Merger 25→1" stock splits on September 7, 2023.
